AAP
ANIK icon

Arax Advisory Partners’s Anika Therapeutics ANIK Stock Holding History

Arax Advisory Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.5K Buy
5,574
+5,252
+1,631% +$77.8K ﹤0.01% 2880
2026
Q1 		$4.67K Buy
322
+36
+13% +$418 ﹤0.01% 2815
2025
Q4 		$2.75K Sell
286
-2,251
-89% -$21.6K ﹤0.01% 3138
2025
Q3 		$23.8K Buy
2,537
+2,229
+724% +$21.3K ﹤0.01% 2186
2025
Q2 		$3.26K Buy
+308
New +$3.89K ﹤0.01% 2390
2024
Q4 		– Sell
-94
Closed -$2.32K – 2444
2024
Q3 		$2.32K Hold
94
– – ﹤0.01% 2009
2024
Q2 		$2.38K Buy
+94
New +$2.44K ﹤0.01% 1901

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Arax Advisory Partners's ANIK Position: Q2 2026 in Review

Arax Advisory Partners increased its Anika Therapeutics (ANIK) stake by 1,631% in Q2 2026, buying an estimated $77.8K and bringing the position to 5,574 shares worth $81.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Arax Advisory Partners first reported a position in ANIK in Q2 2024 and has held it in 7 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Arax Advisory Partners held 5,574 shares of Anika Therapeutics worth $81.5K as of Q2 2026.
  • Arax Advisory Partners bought 5,252 Anika Therapeutics shares in Q2 2026, an estimated $77.8K.
  • Anika Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2880 holding.
  • Arax Advisory Partners first reported a position in Anika Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.